Krystal Biotech, Inc. (KRYS) has a consensus analyst rating of Buy, based on 17 analysts covering the stock. Of those, 17 recommend buying, 0 recommend holding, and 0 recommend selling.
The analyst consensus price target for KRYS is $311.00, representing a +15.2% upside from the current price of $270. Price targets range from a low of $224.00 to a high of $371.00.
